Publication: Piano-stool metal complexes as inhibitors of amyloid-β aggregation in vitro and in vivo
Authors
Vigueras, Gloria ; Sabate, Raimon ; Barrios, Leoní A. ; Caballero, Ana B. ; Hernández García, Samanta ; Bayón, Pau ; Ruiz, José ; Gamez, Patrick ; Gandía Herrero, Fernando
item.page.secondaryauthor
item.page.director
Publisher
Royal Society of Chemistry
publication.page.editor
publication.page.department
DOI
https://doi.org/10.1039/D4QI01460J
item.page.type
info:eu-repo/semantics/article
Description
© 2024, Royal Society of Chemistry. This manuscript version is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by/4.0/. This document is the Published version of a Published Work that appeared in final form in Inorganic Chemistry Frontiers. To access the final edited and published work see https://doi.org/10.1039/D4QI01460J
Abstract
Alzheimer’s disease (AD) is the most common form of dementia worldwide. There is currently no cure for this neurodegenerative disorder, and the available therapies only temporarily lessen some symptoms rather than stopping the disease’s progression. One of the pathological hallmarks in AD brains is the formation of amyloid-β plaques. Transition-metal complexes have aroused great interest as potential chemical modulators of Aβ aggregation thanks to intrinsic features such as the metal oxidation state or the coordination geometry. Four related piano-stool complexes with different metal ions, namely Ru(II), Os(II), Ir(III) and Rh(III), were prepared and their inhibition properties of Aβ aggregation were investigated. It was found that all of them favour an alternative folding pathway, impeding the formation of mature fibres. Moreover, the metal centre seems to play a crucial role in their inhibiting activities. Ru(II) (1), Ir(III) (3) and Rh(III) (4) compounds were remarkable inhibitors of Aβ aggregation in vitro, most particularly 4, and they
appear to share the inhibitory mechanism. However Os(II) complex 2 acts differently on the Aβ aggregation process. In vivo studies using a Caenorhabditis elegans animal model of AD revealed the potential of
complexes 2 and 4, with 2 exhibiting better inhibition potential than 4, thus illustrating the possible occurrence of additional variables to the aggregation process when moving from in vitro experiments to a living organism. To the best of our knowledge, 2 is the first osmium complex reported as an effective inhibitor of amyloid-β aggregation both in vitro and in vivo.
publication.page.subject
Citation
Inorg. Chem. Front.,2024,11,6089–6102
item.page.embargo
Collections
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by/4.0/